by elasmogen | Sep 8, 2021 | News
Expertise in drug discovery and the treatment of life-changing inflammatory diseases has been rewarded with prestigious funding via the UKRI’s Future Leaders Fellowship (FLF) Scheme. Dr Obinna Ubah, heads up Scottish biotechnology company Elasmogen Ltd’s auto-immune...
by elasmogen | Jan 25, 2021 | News
At only one tenth the size of traditional antibodies new VNAR biologics could be used to both treat and protect against SARSCoV-2 infections January 25th 2021: Aberdeen, Scotland: Elasmogen Ltd, the pioneering biopharmaceutical company leading the development of VNAR...
by elasmogen | Dec 9, 2020 | News
New grants across multiple territories cover the use of humanised or de-immunised VNARs for therapeutic applications December 9th 2020: Aberdeen, Scotland: Elasmogen Ltd, the biopharmaceutical company leading the development of soloMERTM biologics, today announces a...
by elasmogen | Jul 8, 2020 | News
New awards for COVID-19 and oncology programs support re-opening of labs in Aberdeen Aberdeen, UK, 8th July 2020: Aberdeen drug discovery pioneer, Elasmogen Ltd has won two new grants worth £374,000 to support programs for COVID-19 and oncology. In April 2020...
by elasmogen | May 5, 2020 | News
Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced an agreement to collaborate and develop novel orally-delivered protein therapeutics (biologics), incorporating proprietary technologies developed by...
